Sep 4, 2019

Multiple Myeloma Update — Part 2: Our interview with Dr Richardson highlights the following topics as well as cases from his practice:

• Approach to treatment decision-making for patients with newly diagnosed MM; strategic use of transplant and evolution of treatment modalities (00:00)
• Case: A woman in her early 70s presents with lambda light chain MM and widespread lytic bone disease (06:15)
• Consideration of daratumumab as a component of induction therapy (08:55)
• Comparison of the efficacy, tolerability and dosing of bortezomib and ixazomib in the up-front setting (11:38)
• Activity and tolerability of melflufen in combination with dexamethasone in patients with R/R MM refractory to pomalidomide and/or daratumumab (13:16)
• Novel mechanism of action of melflufen; synergistic activity in combination with dexamethasone and either bortezomib or daratumumab on the ANCHOR trial (17:41)
• Clinical experience with melflufen-associated cytopenias (23:48)
• Mechanism of action, activity, tolerability and recent FDA approval of the XPO1 inhibitor selinexor in combination with dexamethasone for multiagent-refractory MM (26:38)
• Case: A man in his late 50s with R/R MM receives anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy on a clinical trial (34:22)
• Therapeutic options after disease progression on anti-BCMA CAR T-cell therapy (36:46)
• Frequency and severity of toxicities, including cytokine release syndrome, observed with various BCMA-directed CAR T-cell platforms (38:02)
• Case: A man in his early 60s with R/R MM with the t(11;14) translocation elects to hold ASCT “in reserve” and receives carfilzomib/venetoclax (42:12)
• BELLINI trial: Perspective on outcomes for patients with and without t(11;14) (45:01)

CME information and select publications